注射吸毒者丙型肝炎病毒再治疗研究
本研究基于美国HERO试验的纵向数据,评估注射吸毒者(PWID)在初始直接抗病毒药物(DAA)治疗未获持续病毒学应答(SVR)或再感染后的再治疗结局。未获SVR者启动再治疗较再感染者更迅速(平均471天 vs 784天,P < .001)。
要点
- 25例有SVR结果的再治疗者中24例(96%)获得SVR。
- 未获SVR者启动再治疗平均471天,再感染者平均784天(P < .001)。
核心结论
- 再感染或初始DAA未获SVR后,再治疗的PWID获得的SVR率高于初始DAA治疗。
- 帮助PWID及时获得再治疗对实现HCV消除及个体和公共卫生获益至关重要。
研究设计与样本
- 基于美国HERO研究(8个州、多中心、实用性随机试验)的纵向数据分析,评估2种HCV照护模式在阿片类药物治疗项目和社区诊所中对DAA初治PWID的效果。
- 再治疗 eligible 参与者于2016年9月15日至2021年9月13日期间识别,分析初始SOF/VEL治疗后未获SVR或SVR后再感染者。
- 分类变量采用Fisher精确检验,连续变量均值采用Welch两样本t检验,中位数采用渐近两样本Mood中位数检验。
主要发现
- 25例启动再治疗且有SVR结果者中,24例(96%)获得SVR。
- 未获SVR者启动再治疗平均471天,SVR后再感染者平均784天(P < .001)。
临床怎么用
- 再感染或初始DAA未获SVR的PWID再治疗可获得较高SVR率。
- 协助PWID及时获得再治疗对HCV消除至关重要。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) is a leading cause of infectious disease death in the United States. Although highly effective direct-acting antiviral (DAA) regimens are well established, retreatment among people who inject drugs (PWID) has not been sufficiently studied. This study assessed DAA retreatment outcomes and associated factors. METHODS: We performed analyses of longitudinal data from the HERO Study, a US-based multi-site pragmatic randomized trial conducted in 8 states to evaluate effectiveness of 2 HCV care models among DAA treatment-naïve PWID in opioid treatment programs and community clinics. After initial HERO Study sofosbuvir/velpatasvir (SOF/VEL) treatment, participants eligible for retreatment were identified, from 15 September 2016 to 13 September 2021. This analysis characterizes participants who either did not achieve sustained virologic response (SVR) or were reinfected with HCV post-SVR. We compared categorical variables using Fisher exact test and continuous variables using the Welch 2 sample t test for means and an asymptotic 2-sample Mood median test. RESULTS: One hundred four participants were identified as eligible for retreatment. Less than half, 43 (41.3%), initiated retreatment. Among the 25 who initiated retreatment and for whom SVR results were available, 24 achieved SVR (96%). Participants who did not achieve SVR initiated retreatment more promptly than participants reinfected post-SVR (respectively, 471 vs 784 days on average, P < .001). CONCLUSIONS: After reinfection or not achieving SVR with the first DAA regimen, retreated PWID achieved higher SVR rates than with initial DAA treatment. To attain HCV elimination and benefit individual and public health, assisting PWID with accessing prompt retreatment is crucial.
引用
- Thomas AM, Litwin AH, Tsui JI, et al. Retreatment of Hepatitis C Virus Among People Who Inject Drugs. Clin Infect Dis. 2025. PMID: 40230037. doi:10.1093/cid/ciaf082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。